QTRX Overview

Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.

Wall Street analysts forecast QTRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Quanterix Corp revenue for the last quarter amounts to 43.85M USD, increased 24.73

Quanterix Corp. EPS for the last quarter amounts to -0.49 USD, increased 63.33

Quanterix Corp (QTRX) has 450 emplpoyees as of March 31 2026.

Today QTRX has the market capitalization of 161.00M USD.